BOSTON, Sept 22 (Reuters) - Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40 million to resolve investigations into its marketing and sales of a cholesterol drug, U.S. prosecutors and regulators announced on Friday.
The settlements will resolve long-running investigations into Aegerion, a subsidiary of Canada's Novelion Therapeutics Inc NVLN.O , by the U.S. Justice Department and the U.S. Securities and Exchange Commission related to its drug Juxtapid.
The settlements finalized preliminary agreements Aegerion first disclosed in May 2016. The Cambridge, Massachusetts-based company in November merged with QLT Inc and became a subsidiary of the newly named Novelion Therapeutics.